论文部分内容阅读
目的:探讨鼻NK/T细胞淋巴瘤耐药基因相关蛋白的表达情况,为选择化疗方案提供帮助。方法:免疫组化染色选用的抗体有5种耐药基因相关蛋白,包括:P-糖蛋白(P-170),多药耐药相关蛋白(MRP),肺耐药相关蛋白(LRP),拓扑异构酶Ⅱ(TopoⅡ),谷胱甘肽-S-转移酶(GST-π)。结果:68例NK/T细胞淋巴瘤的耐药基因相关蛋白表达P-170和MRP均为阴性;GST-π阳性33例(48.53%),其中强阳性16例(23.53%),阳性17例(25.00%);LRP阳性14例(20.59%),其中强阳性3例(4.41%),阳性11例(16.18%);TopoⅡ染色Ⅰ级24例(35.29%),Ⅱ级25例(36.76%),Ⅲ级12例(17.65%),Ⅳ级7例(10.29%)。GST-π、LRP和TopoⅡ表达两两比较,其结果均无统计学差异。结论:P-170和MRP可能存在共同的调节因子,且与NK/T细胞淋巴瘤耐药无关。LRP、TopoⅡ和GST-π与NK/T细胞淋巴瘤化疗疗效密切相关。检测NK/T细胞淋巴瘤耐药基因相关蛋白的表达对临床化疗方案的选择提供帮助。
Objective: To investigate the expression of drug resistance related genes in nasal NK / T-cell lymphoma and to provide assistance in selecting chemotherapy regimens. METHODS: The antibodies selected for immunohistochemical staining included five drug-resistance-related proteins including P-170, MRP, LRP, Topo II, GST-π. Results: 68 cases of NK / T cell lymphomas showed negative expression of drug resistance related gene P-170 and MRP; 33 cases (48.53%) had positive GST-π, of which 16 cases were strongly positive (23.53%) and 17 cases were positive (25.00%); LRP positive in 14 cases (20.59%), of which strong positive in 3 cases (4.41%), positive in 11 cases (16.18%); Topo Ⅱ staining in 24 cases (35.29% ), Grade Ⅲ in 12 cases (17.65%), grade Ⅳ in 7 cases (10.29%). GST-π, LRP and Topo Ⅱ pairwise comparison, the results were no significant difference. Conclusion: P-170 and MRP may have common regulatory factors, and have nothing to do with NK / T cell lymphoma resistance. LRP, Topo Ⅱ and GST-π and NK / T cell lymphoma are closely related to the efficacy of chemotherapy. Detection of NK / T cell lymphoma resistance gene-related protein expression of clinical chemotherapy options to help.